Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
Atara Biotherapeutics, Inc. logo

NASDAQ · ATRA

Atara Biotherapeutics, Inc.

Healthcare · Biotechnology

$8.20

Down-$0.28 (-3.30%)

Updated Nov 4, 2026, 4:49 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
128.72M
P/E ratio
37.58
Dividend yield
0.00%
52-week range
$4.30 – $12.45
Volume
17.25K
Avg. volume
71.88K

Price performance · ATRA

ATRA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

ATRA closed at $8.20 after 21 trading sessions, down 15.90% for the selected period.

Last close
$8.20
Period change
-15.90%
Period low
$8.01
Period high
$9.75
Daily close
View OHLC price history
ATRA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$8.34$8.65$8.17$8.2017.25K
Nov 2, 2026$8.05$8.59$8.02$8.4832.05K
Oct 30, 2026$8.53$8.53$7.7231$8.0129.96K
Oct 29, 2026$8.73$8.84$8.2602$8.5311.87K
Oct 28, 2026$8.25$8.66$8.2201$8.6626.85K
Oct 27, 2026$8.44$8.57$8.14$8.3021.7K
Oct 26, 2026$8.68$8.68$8.10$8.3535.27K
Oct 23, 2026$9.37$9.37$8.55$8.5924.32K
Oct 22, 2026$9.23$9.65$8.9709$9.4323.02K
Oct 21, 2026$9.25$9.43$9.17$9.3526.54K
Oct 20, 2026$8.89$9.29$8.88$9.1614.85K
Oct 19, 2026$9.03$9.35$8.96$8.9612.45K
Oct 16, 2026$9.67$9.905$9.18$9.1819.49K
Oct 15, 2026$9.35$9.78$9.185$9.6524.45K
Oct 14, 2026$9.29$9.9899$9.20$9.5639.96K
Oct 13, 2026$9.25$9.54$8.80$9.30532.29K
Oct 12, 2026$9.42$9.58$8.99$9.3826.84K
Oct 9, 2026$9.33$9.5599$9.33$9.4822.15K
Oct 8, 2026$9.42$9.42$8.82$9.2328.94K
Oct 7, 2026$9.62$9.7499$9.37$9.3711.45K
Oct 6, 2026$9.41$9.79$9.05$9.7547.6K

Latest ATRA news

The latest Smart Investors Daily articles mentioning ATRA.

Stock researchCompany · Overview

ATRA research

Overview

Company profile and research snapshot.

Company profile

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.33
Implied upside
—
Analysts
—
ATRA recent ratings
DateFirmRatingTarget
May 18, 2026Freedom BrokerHold—
May 8, 2026Canaccord GenuityBuy—
Jan 13, 2026Canaccord GenuityHold—
Dec 19, 2025Canaccord GenuityBuy—
Mar 11, 2025Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

THOUSAND OAKS, Calif., September 30, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today provided an update that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By